Aura Biosciences Inc (NASDAQ: AURA)’s stock price has gone rise by 14.86 in comparison to its previous close of 5.18, however, the company has experienced a 13.77% increase in its stock price over the last five trading days. globenewswire.com reported 2025-05-15 that BOSTON, May 15, 2025 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an underwritten public offering consisting of (i) 11,735,565 shares of its common stock and accompanying warrants to purchase an aggregate of 2,933,891 shares of common stock and (ii) to certain investors, pre-funded warrants to purchase an aggregate of up to 3,571,435 shares of its common stock at an exercise price of $0.00001 per pre-funded warrant, and accompanying warrants to purchase up to 892,858 shares of its common stock. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase 0.25 of a share of common stock issued for each share of common stock or pre-funded warrant sold. The accompanying common stock warrant has an exercise price of $4.90 per share, is immediately exercisable from the date of issuance and will expire five years from the date of issuance. The combined offering price of each share of common stock and accompanying common stock warrant is $4.90. The combined offering price of each pre-funded warrant and accompanying common stock warrant is $4.89999.
Is It Worth Investing in Aura Biosciences Inc (NASDAQ: AURA) Right Now?
Company’s 36-month beta value is 0.36.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AURA is 44.72M, and currently, short sellers hold a 4.84% ratio of that floaft. The average trading volume of AURA on May 19, 2025 was 277.94K shares.
AURA’s Market Performance
The stock of Aura Biosciences Inc (AURA) has seen a 13.77% increase in the past week, with a 10.19% rise in the past month, and a -25.16% fall in the past quarter. The volatility ratio for the week is 15.05%, and the volatility levels for the past 30 days are at 9.95% for AURA. The simple moving average for the past 20 days is 7.12% for AURA’s stock, with a -25.91% simple moving average for the past 200 days.
Analysts’ Opinion of AURA
Many brokerage firms have already submitted their reports for AURA stocks, with H.C. Wainwright repeating the rating for AURA by listing it as a “Buy.” The predicted price for AURA in the upcoming period, according to H.C. Wainwright is $21 based on the research report published on July 25, 2024 of the previous year 2024.
BTIG Research gave a rating of “Buy” to AURA, setting the target price at $38 in the report published on April 17th of the previous year.
AURA Trading at -1.38% from the 50-Day Moving Average
After a stumble in the market that brought AURA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.93% of loss for the given period.
Volatility was left at 9.95%, however, over the last 30 days, the volatility rate increased by 15.05%, as shares surge +11.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.35% lower at present.
During the last 5 trading sessions, AURA rose by +13.77%, which changed the moving average for the period of 200-days by -40.74% in comparison to the 20-day moving average, which settled at $5.55. In addition, Aura Biosciences Inc saw -27.62% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AURA starting from Gibney Anthony, who proposed sale 1,519 shares at the price of $5.15 back on May 16 ’25. After this action, Gibney Anthony now owns shares of Aura Biosciences Inc, valued at $7,823 using the latest closing price.
Elazzouzi Amy, the Officer of Aura Biosciences Inc, proposed sale 897 shares at $5.49 during a trade that took place back on Apr 16 ’25, which means that Elazzouzi Amy is holding shares at $4,925 based on the most recent closing price.
Stock Fundamentals for AURA
The total capital return value is set at -0.52. Equity return is now at value -56.24, with -48.51 for asset returns.
Based on Aura Biosciences Inc (AURA), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -4.27.
Currently, EBITDA for the company is -85.58 million with net debt to EBITDA at 0.27. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.06.
Conclusion
In a nutshell, Aura Biosciences Inc (AURA) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
